Nectin-4

Nectin-4

Nectin-4 Overview

Molecule Name
Nectin-4
Synonyms
NECTIN4,LNIR, PRR4, PVRL4
Drug Development Progress
Drugs in Clinical Trials29
Approved Drugs1
Highest Development StageApproved
Target Synonym
PRR4,LNIR,Nectin cell adhesion molecule 4,PVRL4,Ig superfamily receptor LNIR,Poliovirus receptor-related protein 4,NECTIN4,Poliovirus Receptor-Related 4,Nectin-4,Nectin 4,EDSS1
Background
Nectin-4 (Nectin Cell Adhesion Molecule 4) is a member of the nectin family of immunoglobulin-like cell adhesion molecules. It is highly expressed during embryonic development but shows limited expression in most normal adult tissues. Nectin-4 is overexpressed in a variety of solid tumors, including bladder, breast, lung, pancreatic and ovarian cancers, and has been associated with tumor growth, invasion and metastasis. Studies have shown that Nectin-4 contributes to tumor progression through multiple signaling pathways, including PI3K/Akt signaling. Due to its restricted expression in normal tissues and elevated expression in malignant tumors, Nectin-4 has emerged as an attractive therapeutic target for cancer diagnosis and treatment.

Nectin-4 Product List

Species
  • Human(13)
  • Mouse(5)
  • Cynomolgus(4)
  • Rat(2)
Tag
  • His Tag(8)
  • His Tag & Avi Tag(8)
  • Fc Tag(4)
  • Fc Tag & Avi Tag(3)
  • Mouse IgG Fc Tag(1)
Host
  • HEK293(24)
Conjugate
  • Unconjugated(12)
  • Biotin-labeled(10)
  • FITC Labeled(1)
  • PE Labeled(1)
Grade
  • RUO(24)
Low Endotoxin
  • Yes(3)
  • No(21)
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&Price
Nectin-4
Mouse Nectin-4 Protein, His Tag (MALS & BLI verified)
Mouse
HEK293
MALSSDS-PAGE
BLI

$360.00

100ug
Nectin-4
HOTAvitag
NE4-H82E7
Biotinylated Human Nectin-4 Protein, His,Avitag™ (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISATR-FRET

$360.00

25ug
Nectin-4
Human Nectin-4 Protein, His Tag, low endotoxin (Mass Spec & MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISASPRBLI

$415.00

100ug
Nectin-4
HOTAvitag
NE4-M82E7
Biotinylated Mouse Nectin-4 Protein, His,Avitag™ (MALS verified)
Mouse
HEK293
MALSSDS-PAGE
ELISA

$360.00

25ug
Nectin-4
Cynomolgus Nectin-4 Protein, Fc Tag (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISA

$360.00

100ug
Nectin-4
Cynomolgus Nectin-4 Protein, His Tag (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISASPRBLI

$360.00

100ug
Nectin-4
Avitag
NE4-C82E5
Biotinylated Cynomolgus Nectin-4 Protein, His,Avitag™ (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISA

$360.00

25ug
Nectin-4
Avitag
NE4-C82F6
Biotinylated Cynomolgus Nectin-4 Protein, Fc,Avitag™ (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISA

$360.00

25ug
Nectin-4
Human Nectin-4 (32-153) Protein, His Tag (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$415.00

100ug
Nectin-4
Human Nectin-4 Protein, Mouse IgG2a Fc Tag (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$355.00

100ug
You Have Viewed 1-10 Of 24 Results
  • 1
  • 2
  • 3

Can’t find what you need?

Submit your requirements and our technical
team will help.

FAQ

Before an anti-Nectin-4 candidate advances into nonclinical studies, what species-specific Nectin-4 proteins and comparable formats are available for cross-species binding assessment?

The portfolio covers human, cynomolgus, mouse and rat Nectin-4 proteins in selected His-tagged, Fc-tagged and AviTag™ formats. Human and cynomolgus His-tagged proteins are HEK293-expressed extracellular-domain constructs with aligned residue boundaries and product-specific SEC-MALS and binding data. Available formats vary for mouse and rat proteins, and protein availability alone does not establish candidate cross-reactivity.

After anti-Nectin-4 leads have been identified, what level of regional epitope characterization can the available Nectin-4 reagents support?

ACROBiosystems provides human Nectin-4 full extracellular-domain proteins spanning residues 32–349 and IgV-domain constructs spanning residues 32–153. This construct coverage supports differentiation between IgV-domain recognition and binding associated with other extracellular regions. It provides regional epitope information rather than residue-level mapping.

During anti-Nectin-4 antibody screening, recombinant proteins support direct target-binding assessment. What complementary tools are available for cell-surface binding characterization?

The HEK293/Human Nectin-4 Stable Cell Line expresses full-length human Nectin-4 on the cell surface and is intended for cell-based antibody-binding assays. Surface expression has been confirmed by flow cytometry. It complements recombinant proteins by supporting confirmation that selected antibodies also recognize cell-surface Nectin-4.

When should I choose a full extracellular-domain Nectin-4 protein versus a truncated construct?

The choice depends on the target region required for your study. Full extracellular-domain proteins support broader binding studies, while truncated constructs can help investigate interactions involving specific regions. Confirm the construct boundaries and validate binding with the intended antibody or partner.

Human Fc-tagged antigens can interfere with anti-human Fc detection in ELISA screening of human or humanized anti-Nectin-4 antibodies. How can this background be reduced?

Using human Nectin-4 with a mouse IgG2a Fc tag separates the antigen tag from the human Fc region of the antibody candidate. The anti-human secondary antibody can then detect the bound human or humanized antibody without recognizing the target protein’s Fc tag, reducing Fc tag-related background. ACROBiosystems provides this Nectin-4 format with SEC-MALS characterization and ELISA binding validation using enfortumab.
Asset Licensing Opportunity
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
SYS-6002SYS-6002; SYS6002; CRB-701Phase 3 ClinicalCSPC Pharmaceutical Group Ltd, Jushi Biopharmaceutical Co Ltd
Carcinoma, Transitional Cell; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms
Details
SHR-A2102SHR-A2102Phase 3 ClinicalShanghai Hengrui Pharmaceutical Co Ltd
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Metastatic breast cancer; Neoplasms; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms
Details
Bulumtatug fuvedotin9MW2821; 9MW-2821; 9-MW2821; 9-MW-2821Phase 3 ClinicalMabwell (Shanghai) Bioscience Co Ltd
Carcinoma; Carcinoma, Transitional Cell; Genital Neoplasms, Female; Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms
Details
Zelenectide pevedotinBT-8009Phase 3 ClinicalBicycle Tx Ltd
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms
Details
BT-7480BT-7480Phase 2 ClinicalBicycle Therapeutics
Neoplasms; Solid tumours
Details
VBC-103AVZO-103; VAC-103; VBC-103; VBC103Phase 2 ClinicalVelaVigo Cayman Ltd
Carcinoma; Carcinoma, Transitional Cell; Solid tumours; Triple Negative Breast Neoplasms
Details
SC-101SC-101Phase 2 ClinicalTianjin Conjustar Biotechnology Co Ltd
Breast Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
Details
SKB-410SKB410; SKB-410; MK-3120Phase 2 ClinicalSichuan Kelun-Biotech Biopharmaceutical Co Ltd
Neoplasms; Solid tumours; Urinary Bladder Neoplasms
Details
PSMA/NKG2DL/FAP-targeted Hi-TCR-T cellsPhase 1 ClinicalShenzhen Misheng Biotechnology Co Ltd
Prostatic Neoplasms; Solid tumours
Details
BA-3361BA3361; BA-3361Phase 1 ClinicalBioatla
Neoplasms
Details
ETx-22ETx-22; LY4101174Phase 1 ClinicalEmergence Therapeutics AG
Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Esophageal Neoplasms; Lung Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Pelvic Neoplasms; Prostatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms
Details
EB-DT-NK-UC101EB-DT-NK-UC101Phase 1 ClinicalBeijing Biotech
Carcinoma; Carcinoma, Transitional Cell; Urethral Neoplasms; Urinary Bladder Neoplasms
Details
68Ga-Nectin-4Phase 1 ClinicalThe First Affiliated Hospital Of Soochow University
Solid tumours
Details
[64Cu]Cu-AKY-1189[64Cu]Cu-AKY-1189Phase 1 ClinicalAktis Oncology Inc
Neoplasms
Details
AKY-1189AKY-1189; [225Ac]Ac-AKY-1189; 225Ac-AKY-1189Phase 1 ClinicalAktis Oncology Inc
Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms
Details
AK-146-D-1AK146D1; AK-146-D1Phase 1 Clinical
Solid tumours
Details
Nectin-4 targeting antibody drug conjugate 2 (Eli Lilly and Company)Phase 1 ClinicalEli Lilly And Company
Neoplasms
Details
Nectin-4 targeting antibody drug conjugate 1 (Eli Lilly and Company)Phase 1 ClinicalEli Lilly And Company
Neoplasms
Details
XKDCT-293XKDCT-293; XKDCT293Phase 1 ClinicalShenzhen Celconta Life Science Co Ltd
Breast Neoplasms
Details
IPH-4502IPH4502; IPH-4502Phase 1 ClinicalInnate Pharma SA
Solid tumours
Details
LY-4052031LY-4052031Phase 1 ClinicalEli Lilly & Company Lilly France
Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Esophageal Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Pelvic Neoplasms; Prostatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms
Details
RNDO-564RNDO-564Phase 1 ClinicalRondo Therapeutics
Carcinoma; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms
Details
ADRX-0706ADRX-0706Phase 1 ClinicalAdcentrx Therapeutics Inc
Carcinoma; Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms
Details
BAT-8007BAT-8007Phase 1 ClinicalBio-Thera Solutions Ltd
Solid tumours
Details
Nectin-4 targeting radiopharmaceutical program (Aktis Oncology)ClinicalAktis Oncology Inc
Solid tumours
Details
[68Ga]Ga-NOTA-RND20ClinicalRenji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine
Digestive System Neoplasms
Details
[18F]F-RESCA-RND20ClinicalRenji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine
Digestive System Neoplasms
Details
CT-341CT-341ClinicalShenzhen Celconta Life Science Co Ltd
Breast Neoplasms
Details
68Ga-N18868Ga-N188; 68-Ga-N-188ClinicalYunnan Baiyao Group Co Ltd
Carcinoma, Transitional Cell; Neoplasms
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Enfortumab vedotinAGS-22C3E; AGS-22C3; ASG-22CE; AGS-M6; ASG-22M6E; DLE8519RWM; ASG-22ME; AGS-22ME; AGS-22M6EApprovedAgensys Inc, Seagen IncPadcev, 备思复United StatesCarcinoma, Transitional CellAstellas Pharma Us Inc2019-12-18
Carcinoma; Carcinoma in Situ; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Transitional Cell; Colorectal Neoplasms; Endometrial Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Ureteral Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms
Details
Customer Reviews
  • O***s2022-07-30
    We used this for an important reagent in discovery campaigns. This was a great product! It came sooner than expected, which was awesome because we were able to easily make deadlines! It was also high quality. We didn't have any problems with it, so I am very happy with the quality of service and product. I will definitely buy again. Thank you very much.
  • 1***82019-10-11
    I Purchased this antigen for monoclonal antibody generation and antibody screening. The purity has been test by SDS-PAGE. It has a single band and no heterologous protein. It was used for antibody screening, and the screened antibody has a good affinity with the antigen.